Burzynski Research Institute

Burzynski Research Institute, Inc. (OTC: BZYR) is a clinical research organization focused on the development of antineoplaston therapy — a proprietary cancer treatment approach developed by Dr. Stanislaw R. Burzynski — and related oncology research programs. According to its website at burzynskiclinic.com, the Burzynski Clinic in Houston, Texas has been treating cancer patients with antineoplaston therapy for more than four decades, attracting patients from around the world seeking alternatives to conventional chemotherapy and radiation for certain types of cancer, including brain tumors such as gliomas and medulloblastomas that have limited treatment options in the standard oncology armamentarium. Antineoplastons are chemical compounds isolated from human blood and urine that Dr. Burzynski hypothesizes have anticancer properties through mechanisms involving the regulation of gene expression in cancer cells.

Burzynski Research Institute's clinical programs, described at burzynskiclinic.com, have been conducted under FDA-authorized Investigational New Drug applications that permit the clinical investigation of antineoplaston therapy in controlled research settings. The company has pursued FDA approval of antineoplaston therapy through the clinical trial process, with Dr. Burzynski maintaining that his patients have achieved responses with antineoplaston treatment, particularly in pediatric brain tumor cases. The Burzynski Clinic and its antineoplaston therapy have been the subject of significant regulatory scrutiny, scientific debate, and media attention, with the FDA having taken enforcement actions against the clinic at various points in its history while the company has continued to operate under IND authorizations.

Burzynski Research Institute represents one of the most controversial and long-running stories in alternative and experimental oncology, with the ongoing debate about antineoplaston therapy reflecting broader questions about the standards of evidence required to establish the safety and efficacy of cancer treatments and the appropriate role of investigational therapies in the care of patients with limited conventional treatment options. According to burzynskiclinic.com, the clinic continues to offer antineoplaston therapy to qualifying patients under its FDA-authorized clinical trial framework, maintaining that its treatment approach represents a potentially important contribution to the treatment of difficult-to-treat cancers for patients who have exhausted or declined conventional treatment options.